Anthony S. Russell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anthony S. Russell has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Walter Maksymowych
Department of Medicine University of Alberta Edmonton Alberta Canada
8 shared publications Barbara Conner-Spady
University of Calgary
5 shared publicationsBoulos Haraoui
University of Montreal
2 shared publicationsCatherine Mallon
University of Alberta Hospital
2 shared publicationsCathy Mallon
2 shared publicationsCecilia Chung
2 shared publications
Latest Publications
- 15 March 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (7) , 1190.2-1190
The Variability of Antinuclear Antibody Testing
The group from the College of American Pathologists1 have carried out an extensive survey of the approaches to antinuclear antibody testing by different laboratories, predominantly in the USA. They reviewed the techniques used and possible reasons for the variations in results.
- 15 March 2021
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 48 (7) , 1190.2-1190
The Variability of Antinuclear Antibody Testing
The group from the College of American Pathologists1 have carried out an extensive survey of the approaches to antinuclear antibody testing by different laboratories, predominantly in the USA. They reviewed the techniques used and possible reasons for the variations in results.
- 10 October 2013
- Published by Springer Nature in Clinical Rheumatology
- Vol. 33 (4) , 561-566
The number needed to offend: a cross-sectional study of potential offensiveness of rheumatic diagnostic labels
This study aims to explore the different connotations and potential offensiveness of ten mechanistic labels in newly referred Mexican patients with rheumatic symptoms as well as in Mexican and Canadian rheumatologists. Patients with musculoskeletal complaints newly referred for a rheumatology assessment were interviewed consecutively before they saw the rheumatologist. Patients were asked to choose one of nine feelings provoked by ten different illness mechanism labels. Rheumatologists gave a medical diagnosis after seeing the patients. Mexican and Canadian rheumatologists were invited to answer a structured questionnaire about their feelings at the moment they identified each of the ten different provided scenarios. Patients' and rheumatologists' feelings were classified as “offended” or “nonoffended.” The “offensive score” was used to calculate a “number needed to offend” (NNO). One hundred and fifty patients were included. Inherited, immunological, and inflammatory labels had the fewest negative connotations (NNOs 17, 12, and 14, respectively), and psychological, functional, idiopathic, and sleep disturbance labels had the most (NNO 2 and 3, respectively). Functional labels were almost four times more offensive than organic labels. Stratified by rheumatologist diagnosis, patients with functional disorders were more accepting of organic-based mechanistic labels. A higher potential to offend was observed when patients with functional somatic conditions were given functional mechanistic labels (NNOs 1 to 4). The survey was completed by 186 Mexican rheumatologists and 71 Canadian rheumatologists. Primarily functional disorders such as somatization and anxiety had a high potential to evoke offensive feelings (NNOs 3 to 7). No significant differences in the NNO were found between Mexican and Canadian rheumatologists. Getting or giving mechanistic/explanatory labels is emotional. Both patients and rheumatologists experienced offended feelings with functional or idiopathic labels.
- 10 October 2013
- Published by Springer Nature in Clinical Rheumatology
- Vol. 33 (4) , 561-566
The number needed to offend: a cross-sectional study of potential offensiveness of rheumatic diagnostic labels
This study aims to explore the different connotations and potential offensiveness of ten mechanistic labels in newly referred Mexican patients with rheumatic symptoms as well as in Mexican and Canadian rheumatologists. Patients with musculoskeletal complaints newly referred for a rheumatology assessment were interviewed consecutively before they saw the rheumatologist. Patients were asked to choose one of nine feelings provoked by ten different illness mechanism labels. Rheumatologists gave a medical diagnosis after seeing the patients. Mexican and Canadian rheumatologists were invited to answer a structured questionnaire about their feelings at the moment they identified each of the ten different provided scenarios. Patients' and rheumatologists' feelings were classified as “offended” or “nonoffended.” The “offensive score” was used to calculate a “number needed to offend” (NNO). One hundred and fifty patients were included. Inherited, immunological, and inflammatory labels had the fewest negative connotations (NNOs 17, 12, and 14, respectively), and psychological, functional, idiopathic, and sleep disturbance labels had the most (NNO 2 and 3, respectively). Functional labels were almost four times more offensive than organic labels. Stratified by rheumatologist diagnosis, patients with functional disorders were more accepting of organic-based mechanistic labels. A higher potential to offend was observed when patients with functional somatic conditions were given functional mechanistic labels (NNOs 1 to 4). The survey was completed by 186 Mexican rheumatologists and 71 Canadian rheumatologists. Primarily functional disorders such as somatization and anxiety had a high potential to evoke offensive feelings (NNOs 3 to 7). No significant differences in the NNO were found between Mexican and Canadian rheumatologists. Getting or giving mechanistic/explanatory labels is emotional. Both patients and rheumatologists experienced offended feelings with functional or idiopathic labels.
- 11 June 2013
- Published by Springer Nature in Clinical Rheumatology
- Vol. 32 (11) , 1657-1659
QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy
- 11 June 2013
- Published by Springer Nature in Clinical Rheumatology
- Vol. 32 (11) , 1657-1659
QuantiFERON testing for cell-mediated immunity to cytomegalovirus in patients with rheumatoid arthritis receiving abatacept and other DMARD therapy
- 2 February 2013
- Published by Springer Nature in Clinical Rheumatology
- Vol. 32 (6) , 875-877
A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience
- 2 February 2013
- Published by Springer Nature in Clinical Rheumatology
- Vol. 32 (6) , 875-877
A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience
- 26 August 2012
- Published by Springer Nature in Clinical Rheumatology
- Vol. 31 (9) , 1289-1292
Subsequent entry biologics/biosimilars: a viewpoint from Canada
We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.
- 26 August 2012
- Published by Springer Nature in Clinical Rheumatology
- Vol. 31 (9) , 1289-1292
Subsequent entry biologics/biosimilars: a viewpoint from Canada
We have reviewed the issues surrounding the advent of biosimilars in the rheumatoid arthritis biologic field. Our proposals emphasize the need to focus primarily on patient safety and to assess the outcomes of therapy both in the short and longer term.
- 1 November 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 88, 7-19
Quality of Life in Patients with Immune-Mediated Inflammatory Diseases
There is no doubt that patients with immune-mediated inflammatory diseases (IMID) have a significantly impaired quality of life (QOL). Pain and disability often leave these patients helpless and frustrated. The recognition that addressing physical and psychological functioning plays a significant role in an overall treatment approach led to the inclusion of QOL measures as secondary outcomes in clinical trials with IMID patients. To that end, both generic and disease-specific instruments have been utilized. Measurement of health-related QOL (HRQOL) and patient-reported outcomes (PRO) in a controlled manner allows for better understanding of the correlation between different aspects of disease activity and QOL. In addition, the effects of different therapeutic options on HRQOL-related outcomes can be further evaluated. This 3-part section describes key QOL-related complaints of patients with IMID affecting joints, skin, or gut. An overview of the strengths and weaknesses of various commonly used HRQOL instruments is provided. Finally, the influence of anti-tumor necrosis factor-α agents on HRQOL outcomes, as assessed in recent clinical trials, is highlighted.
- 1 November 2011
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 88, 7-19
Quality of Life in Patients with Immune-Mediated Inflammatory Diseases
There is no doubt that patients with immune-mediated inflammatory diseases (IMID) have a significantly impaired quality of life (QOL). Pain and disability often leave these patients helpless and frustrated. The recognition that addressing physical and psychological functioning plays a significant role in an overall treatment approach led to the inclusion of QOL measures as secondary outcomes in clinical trials with IMID patients. To that end, both generic and disease-specific instruments have been utilized. Measurement of health-related QOL (HRQOL) and patient-reported outcomes (PRO) in a controlled manner allows for better understanding of the correlation between different aspects of disease activity and QOL. In addition, the effects of different therapeutic options on HRQOL-related outcomes can be further evaluated. This 3-part section describes key QOL-related complaints of patients with IMID affecting joints, skin, or gut. An overview of the strengths and weaknesses of various commonly used HRQOL instruments is provided. Finally, the influence of anti-tumor necrosis factor-α agents on HRQOL outcomes, as assessed in recent clinical trials, is highlighted.
- 1 May 2010
- Published by Oxford University Press (OUP)
- p. 3554-3559
Clinical presentation and diagnosis of rheumatic disease
Most rheumatological diagnoses are made through effective history taking and physical examination rather than investigation.Systemic symptoms, such as weight loss, anorexia, and fever, point to systemic diseases such as rheumatoid arthritis, other polyarthritides, systemic lupus erythematosus, polymyalgia, and vasculitides. Swelling of joints is a symptom commonly reported by patients with no objective evidence of this on examination. Inflammatory arthropathies should not be diagnosed unless the physician is able to identify objective swelling, if necessary by arranging a prompt review during an active episode. Diagnostic criteria for the systemic rheumatic diseases are useful in directing the history taking to verify a suspected diagnosis....
- 1 May 2010
- Published by Oxford University Press (OUP)
- p. 3554-3559
Clinical presentation and diagnosis of rheumatic disease
Most rheumatological diagnoses are made through effective history taking and physical examination rather than investigation.Systemic symptoms, such as weight loss, anorexia, and fever, point to systemic diseases such as rheumatoid arthritis, other polyarthritides, systemic lupus erythematosus, polymyalgia, and vasculitides. Swelling of joints is a symptom commonly reported by patients with no objective evidence of this on examination. Inflammatory arthropathies should not be diagnosed unless the physician is able to identify objective swelling, if necessary by arranging a prompt review during an active episode. Diagnostic criteria for the systemic rheumatic diseases are useful in directing the history taking to verify a suspected diagnosis....
- 29 December 2009
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (3) , 233-239
Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy
- 29 December 2009
- Published by Springer Nature in Clinical Rheumatology
- Vol. 29 (3) , 233-239
Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy
- Open Access
- 8 June 2009
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (6) , 1347.2-1347
Whiplash and the turtle.
- 8 June 2009
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 36 (6) , 1347.2-1347
Open AccessWhiplash and the turtle.
- 12 July 2008
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (9) , 1081-1082
Use of nonsteroidal anti-inflammatory drugs and coxibs in the elderly. Are we following the guidelines?
- 12 July 2008
- Published by Springer Nature in Clinical Rheumatology
- Vol. 27 (9) , 1081-1082
Use of nonsteroidal anti-inflammatory drugs and coxibs in the elderly. Are we following the guidelines?